Gaucher disease is caused by an inherited deficiency of
glucocerebrosidase that manifests with storage of
glycolipids in lysosomes, particularly in macrophages. Available cell lines modeling
Gaucher disease do not demonstrate lysosomal storage of
glycolipids; therefore, we set out to develop two macrophage models of
Gaucher disease that exhibit appropriate substrate accumulation. We used these cellular models both to investigate altered macrophage biology in
Gaucher disease and to evaluate candidate drugs for its treatment. We generated and characterized monocyte-derived macrophages from 20 patients carrying different
Gaucher disease mutations. In addition, we created induced pluripotent stem cell (iPSC)-derived macrophages from five fibroblast lines taken from patients with type 1 or
type 2 Gaucher disease. Macrophages derived from patient monocytes or iPSCs showed reduced
glucocerebrosidase activity and increased storage of
glucocerebroside and
glucosylsphingosine in lysosomes. These macrophages showed efficient phagocytosis of bacteria but reduced production of intracellular
reactive oxygen species and impaired chemotaxis. The disease phenotype was reversed with a noninhibitory small-molecule chaperone
drug that enhanced
glucocerebrosidase activity in the macrophages, reduced
glycolipid storage, and normalized chemotaxis and production of
reactive oxygen species. Macrophages differentiated from patient monocytes or patient-derived iPSCs provide cellular models that can be used to investigate disease pathogenesis and facilitate
drug development.